List of Excipients in Branded Drug ISTURISA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Recordati Rare Diseases Inc	ISTURISA	osilodrostat	55292-320	CELLULOSE, MICROCRYSTALLINE	2035-07-06
Recordati Rare Diseases Inc	ISTURISA	osilodrostat	55292-320	CROSCARMELLOSE SODIUM	2035-07-06
Recordati Rare Diseases Inc	ISTURISA	osilodrostat	55292-320	FERRIC OXIDE RED	2035-07-06
Recordati Rare Diseases Inc	ISTURISA	osilodrostat	55292-320	FERRIC OXIDE YELLOW	2035-07-06
Recordati Rare Diseases Inc	ISTURISA	osilodrostat	55292-320	HYPROMELLOSE	2035-07-06

Isturisa Excipient Strategy and Commercial Opportunities for Osilodrostat

Last updated: September 24, 2026

Isturisa (osilodrostat) is an immediate-release oral tablet for adults with Cushing's disease who are not candidates for pituitary surgery or have persistent or recurrent disease. Its commercial opportunity is driven by rare-disease pricing, chronic dosing, multiple tablet strengths, and limited competition. The principal formulation opportunity is a bioequivalent, lactose-containing immediate-release tablet with strong control of content uniformity, dissolution, impurity growth, and dose flexibility.

What is Isturisa and how is it administered?

Isturisa contains osilodrostat phosphate, a steroidogenesis inhibitor that blocks 11-beta-hydroxylase and aldosterone synthase. The FDA approved Isturisa in March 2020 for adults with Cushing's disease.[1]

Attribute	Isturisa profile
Active ingredient	Osilodrostat phosphate
Therapeutic area	Endocrinology, Cushing's disease
Dosage form	Immediate-release film-coated tablet
FDA-approved strengths	1 mg, 5 mg, and 10 mg
Initial adult dose	2 mg twice daily
Titration	Dose adjusted according to cortisol response and tolerability
Maximum labeled dose	30 mg twice daily
Administration	Oral, with or without food
FDA approval	March 6, 2020
Marketing company in the United States	Recordati Rare Diseases
Regulatory pathway	New drug application
Disease status	Rare endocrine disease

The three commercial strengths are important because treatment is titrated. A generic or authorized alternative would need to support frequent dose adjustments without creating excessive tablet burden.

What excipients are used in Isturisa tablets?

The FDA label identifies a conventional solid-dose excipient system. The inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, talc, titanium dioxide, and colorants.[1]

Excipient category	Isturisa function	Commercial relevance
Lactose monohydrate	Diluent and tablet-mass builder	Creates a potential lactose-intolerance and labeling issue
Microcrystalline cellulose	Direct-compression filler and dry binder	Supports hardness and compressibility
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and dissolution
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Colloidal silicon dioxide	Glidant and moisture-flow aid	Supports powder flow and content uniformity
Hypromellose	Film-coating polymer	Protects the tablet and supports identification
Talc	Coating aid and anti-tacking agent	Affects coating performance
Titanium dioxide and iron oxides	Opacifying and coloring agents	Support strength differentiation and product identification

The label does not disclose quantitative excipient levels. That limits direct replication of the reference formulation, but it does not prevent an ANDA applicant from developing a qualitatively or quantitatively different formulation that meets pharmaceutical equivalence and bioequivalence requirements.

What excipient strategy is appropriate for an Isturisa generic?

A conventional direct-compression or dry-granulation platform is the most commercially practical approach. Osilodrostat tablets require reliable low-dose content uniformity, particularly for the 1 mg strength, while also accommodating 5 mg and 10 mg products.

Low-dose uniformity

The 1 mg tablet creates the main development challenge. The active ingredient represents a small fraction of tablet mass, increasing the risk of segregation and assay variability. Suitable strategies include:

• Premixing osilodrostat with microcrystalline cellulose or another carrier.
• Using a controlled geometric dilution process.
• Applying ordered mixing or carrier-based agglomeration.
• Using dry granulation if powder-flow data are inadequate.
• Controlling lubricant addition time to prevent dissolution loss.
• Establishing blend uniformity controls at commercial scale.

A formulation that uses excessive filler to solve low-dose uniformity can increase tablet size and reduce patient convenience. The preferred design is a compact tablet platform with a common manufacturing process across strengths.

Dissolution control

Croscarmellose sodium and microcrystalline cellulose provide a conventional route to rapid disintegration. The formulation should control:

• Disintegrant level and distribution.
• Tablet hardness and compression force.
• Magnesium stearate concentration.
• Lubrication time.
• Coating weight gain.
• Dissolution across relevant pH conditions.

Because Isturisa is administered with or without food, a generic product should demonstrate robust dissolution under fed and fasted conditions. A formulation that is too hydrophobic or over-lubricated could introduce avoidable bioequivalence risk.

Lactose-free opportunity

The reference formulation contains lactose monohydrate. A lactose-free product could replace lactose with mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose, or a combination of microcrystalline cellulose and low-substituted hydroxypropyl cellulose.

The commercial value of a lactose-free version is limited by the small Cushing's disease population, but it may help differentiate the product in specialty-pharmacy channels. The substitution must preserve:

• Tablet tensile strength.
• Disintegration time.
• Moisture stability.
• Osilodrostat assay and impurity profile.
• Dissolution equivalence.
• Color and appearance across strengths.

A lactose-free formulation is a product-positioning option, not necessarily a patent barrier. The economic benefit depends on whether the manufacturer can secure preferred formulary placement or specialty-distribution access.

What formulation patents protect Isturisa?

The principal intellectual-property risk for an Isturisa competitor is likely to arise from active-ingredient, manufacturing, and method-of-use rights rather than from the disclosed excipient list.

The FDA label identifies a conventional formulation and does not claim a proprietary controlled-release system, multiparticulate delivery system, transdermal platform, or complex drug-device combination.[1] That profile generally reduces the probability that the basic excipient combination alone creates a durable formulation barrier.

Relevant patent categories

Patent category	Potential scope	Generic risk
Osilodrostat composition patents	Chemical compound and salts	High if unexpired
Process patents	Synthesis, purification, polymorph control	Medium to high
Pharmaceutical composition patents	Osilodrostat with specified excipients or ratios	Medium
Method-of-use patents	Treatment of Cushing's disease and cortisol control	Medium
Formulation patents	Release, stability, particle size, or tablet architecture	Low to medium based on claim scope
Manufacturing know-how	Blend uniformity, impurity control, scale-up	Commercial rather than formal patent risk

An ANDA applicant should distinguish three different barriers: FDA regulatory exclusivity, listed patents in the Orange Book, and non-listed manufacturing or know-how rights. These barriers have different legal effects.

When does Isturisa lose exclusivity?

Isturisa received FDA approval in 2020. New chemical entity exclusivity generally lasts five years from approval, subject to statutory exceptions. For Isturisa, that period would ordinarily have reached its endpoint in 2025. The product also received orphan-drug designation, which generally provides seven years of marketing exclusivity for the approved indication from the date of approval. On that basis, orphan exclusivity would ordinarily extend to March 6, 2027.[1][2]

Exclusivity or protection	Indicative timing	Commercial effect
New chemical entity exclusivity	Through approximately 2025	Delayed certain ANDA submissions during the initial period
Orphan-drug exclusivity	Through approximately March 6, 2027	Blocks approval of the same drug for the same indication, subject to statutory exceptions
Listed patent protection	Patent-specific	May extend beyond regulatory exclusivity
Pediatric exclusivity	Not established from the core FDA label	Would add six months only if granted
Data protection for generic applicants	Depends on ANDA and Orange Book status	Affects timing of approval rather than product design

Orphan exclusivity is indication-specific. It does not necessarily prevent approval of another osilodrostat product for a legally distinct indication, nor does it eliminate the need to evaluate patent claims.

What is the Orange Book status of Isturisa?

The Orange Book determines which patents an ANDA applicant must address through Paragraph IV or other certification. Listed patents may cover the active ingredient, an approved method of use, or a formulation.

The commercial implication is clear: a generic applicant cannot rely only on the absence of a complex excipient technology. It must evaluate every current Orange Book listing, its expiration date, pediatric extensions, and the scope of the approved labeling.

Paragraph IV exposure

A Paragraph IV certification can trigger patent litigation if the brand owner sues within the statutory period. The principal outcomes are:

1. A 30-month stay of ANDA approval if litigation is timely filed.
2. Earlier launch following a successful non-infringement or invalidity position.
3. A settlement that sets a licensed or agreed entry date.
4. Approval after patent expiry or final resolution.

For Isturisa, the most credible generic entry scenario is a tablet that avoids unnecessary formulation claims while challenging or waiting out any remaining compound and method-of-use rights.

What manufacturing and IP barriers affect osilodrostat products?

Osilodrostat manufacturing may create practical barriers even where the finished tablet is simple. The main technical issues are likely to include impurity control, solid-state consistency, low-dose blending, and supply reliability.

Manufacturing barriers

A commercial supplier must control:

• Starting-material and intermediate impurity carryover.
• Residual solvents.
• Solid-state form and particle-size distribution.
• Blend segregation during transfer and compression.
• Tablet-to-tablet assay variation.
• Stability under moisture and heat stress.
• Color matching across 1 mg, 5 mg, and 10 mg strengths.

These factors may support trade secrets or process patents. They do not necessarily prevent generic entry, but they can increase development cost and delay scale-up.

Supply-chain opportunity

The small patient population favors a high-value, low-volume manufacturing model. A contract development and manufacturing organization could compete by offering:

• Multi-strength tablet manufacture.
• Highly contained hormone and steroid processing.
• Low minimum batch sizes.
• Specialty-pharmacy packaging.
• Stability-indicating analytical methods.
• Regional supply for the United States, Europe, and other regulated markets.

A supplier with existing endocrine, rare-disease, or potent-compound infrastructure would have a stronger position than a general tablet manufacturer.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have several routes to participate in the Isturisa market without owning the active ingredient.

Direct formulation support

The most immediate opportunity is a high-performance direct-compression system that improves low-dose uniformity and dissolution. A supplier could provide a co-processed filler-disintegrant platform based on microcrystalline cellulose, mannitol, or starch derivatives.

Lactose-free positioning

A lactose-free excipient system can support product differentiation. The opportunity is most credible if it provides a measurable manufacturing or patient benefit, such as:

• Improved powder flow.
• Lower tablet weight.
• Better moisture stability.
• Faster disintegration.
• Reduced variability at the 1 mg strength.

A lactose-free formulation without a measurable performance advantage would have limited commercial leverage.

Film-coating systems

A ready-to-use coating system can simplify three-strength color matching and reduce development time. Because tablet strengths must be visually distinguishable, coating reproducibility has operational value.

Analytical and stability services

Specialty laboratories can support generic development through:

• Dissolution method development.
• Blend-uniformity testing.
• Forced-degradation studies.
• Solid-state characterization.
• Extractables and leachables testing for packaging.
• Comparative stability programs.

How does Isturisa compare with competing Cushing's disease treatments?

Isturisa competes with products that act through different mechanisms and delivery routes.

Product	Active ingredient	Main route	Competitive point
Isturisa	Osilodrostat	Oral tablet	Oral steroidogenesis inhibition; dose titration
Signifor/Signifor LAR	Pasireotide	Injection	Somatostatin-pathway treatment; injectable burden
Korlym	Mifepristone	Oral tablet	Glucocorticoid receptor antagonism; different monitoring profile
Ketoconazole products	Ketoconazole	Oral tablet	Older steroidogenesis approach; broader interaction concerns
Recorlev	Levoketoconazole	Oral tablet	Steroidogenesis inhibition with separate formulation and patent estate

The main commercial advantage of Isturisa is oral administration with multiple strengths. The main competitive risks are treatment switching, payer management, generic entry, and alternative products that achieve cortisol control with different monitoring requirements.

What generic launch risks exist for Isturisa?

A first generic entrant would face a narrow but potentially valuable market. Key risks include:

• Small eligible patient population.
• Orphan-drug exclusivity through approximately March 2027.
• Patent litigation over active-ingredient or method-of-use claims.
• Limited prescriber concentration in endocrinology.
• Specialty-pharmacy distribution requirements.
• Need for reliable supply across three strengths.
• Potential price compression after multiple entrants.
• Brand contracting and patient-support programs.

The most attractive launch model is a focused specialty generic with all three strengths, robust supply, and a formulation that avoids unnecessary excipient or manufacturing patent exposure.

Key Takeaways

• Isturisa is an immediate-release osilodrostat tablet available in 1 mg, 5 mg, and 10 mg strengths.
• Its disclosed excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, talc, titanium dioxide, and colorants.
• The 1 mg strength creates the main formulation challenge because of low-dose content uniformity.
• A lactose-free formulation is commercially possible but offers differentiation only if it improves manufacturability, stability, or patient positioning.
• The most important intellectual-property risks are likely to involve compound, process, and method-of-use rights rather than the basic excipient combination.
• New chemical entity exclusivity would ordinarily have ended in 2025; orphan-drug exclusivity would ordinarily extend to March 6, 2027.
• A generic launch strategy should prioritize all three strengths, direct compression or dry granulation, rapid dissolution, low-dose uniformity, and specialty-channel supply.
• Excipient suppliers can compete through co-processed fillers, lactose-free systems, ready-to-use film coatings, and analytical support.

FAQs About Isturisa Excipient and Generic Opportunities

Does Isturisa contain lactose?

Yes. The FDA-approved label identifies lactose monohydrate as an inactive ingredient.[1]

Can a generic Isturisa tablet use different excipients?

Yes. An ANDA applicant can use a different excipient composition if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and stability requirements.

Is Isturisa an extended-release product?

No. Isturisa is an immediate-release film-coated tablet.

Which Isturisa strength is hardest to formulate?

The 1 mg strength is generally the most demanding because the low active-ingredient load increases the risk of blend segregation and content-uniformity failure.

Is a lactose-free Isturisa generic commercially attractive?

It can be attractive as a differentiation strategy, but the value depends on whether the formulation improves manufacturing performance, stability, tablet size, or specialty-pharmacy positioning.

References

1. U.S. Food and Drug Administration. (2020). Isturisa (osilodrostat) tablets: Prescribing information. Recordati Rare Diseases, Inc.

2. U.S. Food and Drug Administration. (2023). Orphan drugs and orphan-drug exclusivity. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Recordati S.p.A. (2024). Annual report and financial statements. Recordati.